THURSDAY, Dec. 18, 2014 (HealthDay News) — Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer’s ear, clinically known as acute otitis externa.
The infection of the outer ear and ear canal, most often caused by ear canal bacteria, has typical symptoms including pain, swelling, redness and discharge, the FDA said in a news release.
The drug’s safety and effectiveness were evaluated in a clinical study of more than 1,200 people, aged 6 months to 85 years. The most common side effects were ear itching and nausea.
Xtoro is produced by Alcon Laboratories, based in Fort Worth, Texas.
More information
The FDA has more about this approval.
Copyright © 2025 HealthDay. All rights reserved.